Ali Naderi, MD, CCST (UK)
- Associate Researcher (Associate Professor)
Clinical and Translational Research
University of Hawaii Cancer Center
- Doctorate in Medicine and Biomedical Sciences (MD)
Shahid-Beheshti University of Medical Sciences, Tehran
- Residency (Internal Medicine)
Wayne State University, Michigan
University of Maryland, Baltimore
- Specialist Certification (CCST in Medical Oncology)
The Medical Royal Colleges, United Kingdom
- Diplomate (Medical Oncology)
American Board of Internal Medicine
- Fellowship (Medical Oncology)
Mayo Clinic, Minnesota
- Postdoctoral Research Fellowship (Cancer Biology)
University of Cambridge, United Kingdom
Dr. Naderi is a physician-scientist and medical oncologist with a focus on breast cancer research. He joined the University of Hawaii Cancer Center in January 2016 and previously held faculty positions at the University of Iowa and the University of Queensland. Dr. Naderi currently has research projects to study the molecular functions of Prolactin-Induced Protein (PIP) and Androgen Receptor (AR) in breast cancer. In addition, Dr. Naderi's group is interested in the field of pharmacometabolomics for anti-cancer therapies.
PIP also known as GCDFP-15 is one of the most abundant proteins expressed in breast cancer and is used as a characteristic biomarker in the diagnosis of this disease. Dr. Naderi's laboratory has demonstrated that PIP has a significant function in the cell cycle progression of breast cancer cells and his group currently studies the molecular mechanisms of PIP function and translational applications of this widely expressed protein in breast cancer. Furthermore, Dr. Naderi's laboratory was one of the first to identify the role of AR signaling in Estrogen Receptor-negative tumors and contributed to the characterization of "molecular apocrine" subtype of breast cancer using functional and genomic studies. In this respect, Dr. Naderi's group currently studies the molecular functions and novel target genes of AR in breast cancer and investigates the therapeutic implications of AR inhibition in the management of breast cancer patients.
- Naderi A. (2015). Coagulation factor VII is regulated by androgen receptor in breast cancer. Experimental Cell Research, Experimental Cell Research, 331(1): 239-250.
- Vanneste M, Naderi A. (2015). Prolactin-Induced Protein regulates cell adhesion in breast cancer. Biochemical and Biophysical Research Communications, 468(4): 850-856.
- Naderi A, Vanneste M. (2014). Prolactin-Induced Protein is required for Cell Cycle Progression in Breast Cancer. Neoplasia,16(4): 329-342.e14.
- Naderi A, Meyer M. (2012). Prolactin-Induced Protein mediates cell invasion and regulates Integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Research, 14(4): R111.
- Naderi A, Meyer M, Dowhan DH. (2012). Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia, 14(4): 283-296.
- Naderi A, Liu J, Francis GD. (2012). A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. International Journal of Cancer, 130(1): 71-82.
Publication list via PubMed